Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?

Detalles Bibliográficos
Autores principales: Lemmon, Christopher, Pennell, Nathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578493/
https://www.ncbi.nlm.nih.gov/pubmed/33145076
http://dx.doi.org/10.21037/jtd-20-1817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578493/
https://www.ncbi.nlm.nih.gov/pubmed/33145076
http://dx.doi.org/10.21037/jtd-20-1817

Ejemplares similares